Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001104659-24-052919
Filing Date
2024-04-26
Accepted
2024-04-26 16:06:22
Documents
14
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K/A tm2411819d1_10ka.htm   iXBRL 10-K/A 154241
2 EXHIBIT 31.1 tm2411819d1_ex31-1.htm EX-31.1 4239
  Complete submission text file 0001104659-24-052919.txt   393785

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA enzn-20231231.xsd EX-101.SCH 3006
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE enzn-20231231_lab.xml EX-101.LAB 36884
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE enzn-20231231_pre.xml EX-101.PRE 24140
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2411819d1_10ka_htm.xml XML 6180
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Filer) CIK: 0000727510 (see all company filings)

EIN.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 000-12957 | Film No.: 24883613
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)